The CNIO ruled out "very weak" the patent with which Barbacid has already raised 3.5 million against pancreatic cancer

The European Patent Office said it did not see sufficient “novelty” or “inventive activity” in patent 107, which the CNIO renounced in favor of the scientist, who already in 2011 announced an advance against lung cancer that later never reached humans. Read

Source